Meeting report: the 2021 FSHD International Research Congress.
Meeting report: the 2021 FSHD International Research Congress.
复制标题
DOI:
10.1186/s13395-022-00287-8
复制
发表时间:
2022-01-17
期刊:
影响因子:
4.9
通讯作者:
Harper SQ
中科院分区:
文献类型:
--
作者:
Jagannathan S;de Greef JC;Hayward LJ;Yokomori K;Gabellini D;Mul K;Sacconi S;Arjomand J;Kinoshita J;Harper SQ
Facioscapulohumeral muscular dystrophy (FSHD) is the second most common genetic myopathy, characterized by slowly progressing and highly heterogeneous muscle wasting with a typical onset in the late teens/early adulthood. Although the etiology of the disease for both FSHD type 1 and type 2 has been attributed to gain-of-toxic function stemming from aberrant DUX4 expression, the exact pathogenic mechanisms involved in muscle wasting have yet to be elucidated. The 2021 FSHD International Research Congress, held virtually on June 24–25, convened over 350 researchers and clinicians to share the most recent advances in the understanding of the disease mechanism, discuss the proliferation of interventional strategies and refinement of clinical outcome measures, including results from the ReDUX4 trial, a phase 2b clinical trial of losmapimod in FSHD [NCT04003974].
登录
查看更多内容
影响因子:
3.7
作者:
Jones T;Jones PL
通讯作者:
Jones PL
DOI:
10.1038/mt.2016.111
发表时间:
2016-08
期刊:
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子:
--
作者:
通讯作者:
--
影响因子:
3.3
作者:
Gros M;Nunes AM;Daoudlarian D;Pini J;Martinuzzi E;Barbosa S;Ramirez M;Puma A;Villa L;Cavalli M;Grecu N;Garcia J;Siciliano G;Solé G;Juntas-Morales R;Jones PL;Jones T;Glaichenhaus N;Sacconi S
通讯作者:
Sacconi S
影响因子:
16.6
作者:
Bosnakovski D;Chan SSK;Recht OO;Hartweck LM;Gustafson CJ;Athman LL;Lowe DA;Kyba M
通讯作者:
Kyba M
影响因子:
12.4
作者:
Wallace, Lindsay M.;Liu, Jian;Harper, Scott Q.
通讯作者:
Harper, Scott Q.